{"nctId":"NCT01361308","briefTitle":"Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)","startDateStruct":{"date":"2011-05"},"conditions":["Postmenopausal Symptoms"],"count":614,"armGroups":[{"label":"Brisdelle (paroxetine mesylate)","type":"EXPERIMENTAL","interventionNames":["Drug: Brisdelle (paroxetine mesylate)"]},{"label":"Placebo Capsules","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo capsules"]}],"interventions":[{"name":"Brisdelle (paroxetine mesylate)","otherNames":["Former Names: Mesafem Capsules or","LDMP (Low-Dose Mesylate salt of Paroxetine)"]},{"name":"Placebo capsules","otherNames":["Sugar pill"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Female, ≥ 40 years of age at screening (inclusive)\n2. Reported more than 7-8 moderate to severe hot flashes per day (average) or 50-60 moderate to severe hot flashes per week for at least 30 days prior to the screening visit\n3. Spontaneous amenorrhea for at least 12 consecutive months or\n4. Amenorrhea for at least 6 months and meet the biochemical criteria for menopause or\n5. Bilateral salpingo-oophorectomy ≥ 6 weeks with or without hysterectomy\n\nExclusion Criteria:\n\n1. Known non-responder to previous Selective serotonin reuptake inhibitor (SSRI) or Serotonin norepinephrine reuptake inhibitor (SNRI) treatment for VMS\n2. History of self injurious behavior\n3. History of clinical diagnosis of depression or treatment for depression\n4. History of clinical diagnosis of borderline personality disorder\n5. Use of an investigational study medication within 30 days prior to screening or during the study\n6. Concurrent participation in another clinical trial or previous participation in this trial\n7. Family of investigational-site staff","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change in Frequency of Moderate to Severe VMS From Baseline at Week 4 and Week 12.","description":"Subjects recorded the number of hot flashes per week using an electronic diary. The results reported are not hot flashes per week.\n\nThe results reported are:\n\n* Mean Baseline frequency of moderate to severe VMS\n* Mean change in frequency of moderate to severe VMS from baseline to Week 4\n* Mean change in frequency of moderate to severe VMS from baseline to Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.79","spread":"4.87"},{"groupId":"OG001","value":"11.65","spread":"4.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.71","spread":"4.00"},{"groupId":"OG001","value":"-3.36","spread":"4.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.22","spread":"4.53"},{"groupId":"OG001","value":"-5.33","spread":"5.31"}]}]}]},{"type":"SECONDARY","title":"Clinical Meaningfulness Anchored to Patient Global Improvement (PGI-I) (%)","description":"A patient improvement scale questionnaire was used during participant visits.\n\nThe clinical meaningfulness of the observed treatment effect was demonstrated by performing the following analysis:\n\nSubjects were categorized in to 2 groups (satisfied and unsatisfied). Based on a 7 point patient global impression (PGI) questionnaire which assesses the subject improvement in VMS. Subjects were considered satisfied with their treatment if their response to the question \"Compared to before starting the study medication, how would you describe your hot flushes now?\" is 'Very much better' (1) or 'Much better' (2) or 'A little better' (3) and will be considered unsatisfied if their response to the same question is 'No change' (4) or 'A little worse' (5) or 'Much worse' (6) or 'Very much worse' (7). Receiver Operator Curve (ROC) analysis was performed on the combined data.\n\nSubjects who were satisfied with their treatment were considered to have a treatment effect with clinical meaningfulness","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Number of Awakenings Due to Hot Flashes, Median","description":"Participants completed a electronic diary to report nightime awakenings. Subjects took study drug once daily at bedtime and they were instructed to complete daily hot flash and sleep diaries to record the number of hot flashes daily, the severity of each episode of hot flash and total number of awakenings due to hot flashes.\n\nThe diary data was used to evaluate and compare the treatment groups, on the change from baseline to Week 4 and Week 12, in the total number of awakenings due to hot flashes. The total number of awakenings due to hot flashes in the run-in period was used as baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":null},{"groupId":"OG001","value":"-7.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.00","spread":null},{"groupId":"OG001","value":"-11.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Frequency of Moderate to Severe Hot Flashes Frequency From Baseline (BMI <32 kg/m2, Week 4 and Week 12), Median","description":"Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.\n\nFor the BMI \\<32 kg/m2 subgroup, the mean weekly reduction in frequency of moderate to severe hot flashes from Baseline was calculated for Week 4 and Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.00","spread":null},{"groupId":"OG001","value":"-23.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.00","spread":null},{"groupId":"OG001","value":"-35.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Frequency of Moderate to Severe Hot Flashes Frequency From Baseline (BMI ≥32 kg/m2, Week 4 and Week 12), Median","description":"Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.\n\nFor the BMI ≥32 kg/m2 subgroup, the mean weekly reduction in frequency of moderate to severe hot flashes from Baseline was calculated for Week 4 and Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.00","spread":null},{"groupId":"OG001","value":"-19.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.00","spread":null},{"groupId":"OG001","value":"-37.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Severity of Moderate to Severe Hot Flashes From Baseline (BMI <32 kg/m2, At Week 4 and Week 12), Median","description":"Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.\n\nFor the BMI \\<32 kg/m2 subgroup, the mean weekly reduction in the severity of moderate to severe hot flashes from Baseline was calculated at Week 4 and Week 12.\n\nSubjects recorded the number of hot flashes per week using an electronic diary. Severity score for hot flashes for each subject was calculated as the sum of 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of moderate and severe hot flashes.\n\nWeekly Severity Score = (2•Fm +3•FS)/(Fm + FS) Daily Severity Score = {(2•F) m +3•FS)/(Fm + FS)}/7 Where, Fm= Frequency of Moderate Hot Flashes Fs = Frequency of Severe Hot Flashes The calculated severity score is reported below.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.055","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.043","spread":null},{"groupId":"OG001","value":"-0.010","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Severity of Moderate to Severe Hot Flashes From Baseline (BMI ≥32 kg/m2, Week 4 and Week 12), Median","description":"Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.\n\nFor the BMI ≥32 kg/m2 subgroup, the mean weekly reduction in the severity of moderate to severe hot flashes from Baseline was calculated at Week 4 and Week 12.\n\nSubjects recorded the number of hot flashes per week using an electronic diary. Severity score for hot flashes for each subject was calculated as the sum of 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of moderate and severe hot flashes.\n\nWeekly Severity Score = (2•Fm +3•FS)/(Fm + FS) Daily Severity Score = {(2•F) m +3•FS)/(Fm + FS)}/7 Where, Fm= Frequency of Moderate Hot Flashes Fs = Frequency of Severe Hot Flashes The calculated severity score is reported below.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.023","spread":null},{"groupId":"OG001","value":"-0.014","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.079","spread":null},{"groupId":"OG001","value":"-0.030","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Greene Climacteric Scale (GCS) at Week 4 and Week 12, Total Score, Median","description":"The Greene Climacteric Scale (GCS) was used for this measurement. The scale has 21 questions and measures symptoms in 4 areas; these are psychological (anxiety and depression), physical, vasomotor, and libido.\n\nThe severity of the symptom was scored as: 0=none, 1=mild, 2=moderate, and 3=severe. Anxiety was determined by using the sum of scores 1 to 6, and depression was determined by using the sum of scores 7 to 11. Physical aspects were determined by using the sum of scores 12 to 18; vasomotor aspects were determined by using the sum of scores 19 to 20; and libido was determined by using the score for question 21.\n\nThe total GCS score ranges from \"0\" to \"63\" which is the sum of all the scores for the 21-symptom assessment questions in this scale. Each subject's total GCS score at baseline and at Week 4 and Week 12 were used to calculate change from baseline in these symptoms. The change from baseline is reported below.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.00","spread":null},{"groupId":"OG001","value":"-2.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.00","spread":null},{"groupId":"OG001","value":"-3.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders","description":"Participants reported the number of hot flashes using an electronic diary. Participants who hd a ≥50% reduction in hot flash frequency were defined as responders. The percent of responders is presented below.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.20","spread":null},{"groupId":"OG001","value":"29.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.83","spread":null},{"groupId":"OG001","value":"44.92","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patient Global Improvement (PGI) Scale Responders (%)","description":"Percentage of PGI Responders: Subject's overall improvement in VMS from baseline assessed using the Patient Global Improvement (PGI) scale. Responders: Subjects Achieving a Score of \"Very Much Better\" Or \"Much Better\" Or \"A Little Better\".\n\nNon Responders: Subjects with a Score of \"No Change\" Or \"A Little Worse\" Or \"Much Worse\" Or \"Very Much Worse\".\n\nPatient Global Improvement (PGI) scale is described below:\n\nCompared to before starting study medication, how would you describe your hot flushes now? 0 = Not assessed\n\n1. = Very much better\n2. = Much better\n3. = A little better\n4. = No change\n5. = A little worse\n6. = Much worse\n7. = Very much worse","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.21","spread":null},{"groupId":"OG001","value":"61.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.82","spread":null},{"groupId":"OG001","value":"64.60","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Daytime and Nighttime Responders, Numerical Rating Scale (NRS)","description":"Subject's overall improvement in VMS from Baseline assessed using the Numerical Rating Scale (NRS) The NRS is measured on a scale of 0 to 10 on how bothered the subject was by her VMS (0=not bothered at all and 10=very much bothered).\n\nThe measure being reported below is percentage of responders who had an improvement in NRSscore at Week 4 and Week 12 compared to baseline. A responder is defined as a subject who had an improvement in the NRS score. An improvement is defined as a score ≤5 on each question.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.00","spread":null},{"groupId":"OG001","value":"30.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.51","spread":null},{"groupId":"OG001","value":"45.72","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Arizona Sexual Experience Scale (ASEX, Week 4 and Week 12) Total Score","description":"The Arizona Sexual Experiences Scale (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with the higher scores indicating more sexual dysfunction.\n\nThe sum of the scores for all 5 items was calculated at Week 4 and Week 12. The results presented below are change from baseline at Week 4 and Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":"3.28"},{"groupId":"OG001","value":"-0.43","spread":"2.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"3.77"},{"groupId":"OG001","value":"-0.61","spread":"3.30"}]}]}]},{"type":"SECONDARY","title":"Effect of Paroxetine Mesylate Capsules on Percent Improvement of Hot Flash Interference From Baseline at Week 4 and Week 12, Hot Flash Related Daily Interference Scale (HFRDIS)","description":"Interference of hot flashes was measured by using the hot flash-related daily interference scale (HFRDIS). The HFRDIS is a 10-item scale that measures the degree to which hot flashes interfere with 9 daily activities and the tenth item measures the degree to which hot flashes interfere with each of the other items. Subjects can score for each item on a scale from 0 to 10 where 0 = Do not interfere and a score of 10 = Completely interferes.\n\nThe measure being reported below is percentage of responders who had an improvement in HFRDIS score at Week 4 and Week 12 compared to baseline. A responder is defined as a subject who had an improvement in the HFRDIS score. An improvement is defined as a score ≤3 on each question.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.98","spread":null},{"groupId":"OG001","value":"32.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.67","spread":null},{"groupId":"OG001","value":"21.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Responders Improvement in VMS From Baseline Using the Clinical Global Impression (CGI) Scale.","description":"Proportion of NRS Responders: Subject's overall improvement in VMS from Baseline was assessed using the Numerical Rating Scale (NRS)\n\nThe Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.\n\nResponders: Subjects Achieving a Score of \"Very Much Improved\" Or \"Much Improved\" Or \"Minimally Improved\".\n\nNon Responders: Subjects with a Score of \"No Change\" Or \"Minimally Worse\" Or \"Much Worse\" Or \"Very Much Worse\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.93","spread":null},{"groupId":"OG001","value":"57.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.88","spread":null},{"groupId":"OG001","value":"63.92","spread":null}]}]}]},{"type":"SECONDARY","title":"Effect of Brisdelle (Paroxetine Mesylate) Capsules on Anxiety and Depression","description":"Depression \\& anxiety were measured by using the Hospital Anxiety \\& Depression Scale (HADS).\n\nThe HADS was developed to assess anxiety \\& depression. It is meant to differentiate symptoms of depression with those of anxiety.\n\nNumber of items: 14 (7 questions relating to anxiety; 7 questions relating to depression).\n\nResponses are based on the relative frequency of symptoms over the past week, using a four point scale ranging from 0 (not at all) to 3 (very often indeed).\n\nResponses are summed to provide separate scores for anxiety and depression symptomology with possible scores ranging from 0 to 21 for each scale.\n\nThe results presented below are the percentage of participants with abnormal HADS Scores for both Abnormal Anxiety \\& Abnormal Depression at Week 4 and Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.56","spread":null},{"groupId":"OG001","value":"3.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":null},{"groupId":"OG001","value":"2.75","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Mood","description":"Mood was measured by using the Profile of Mood States (POMS) questionnaire. The Profile of Moods States (POMS) is a 65-item multi-dimensional measure that provides a method of assessing transient, fluctuating active mood states. Key areas that are measured include: tension-anxiety, anger-hostility, fatigue-inertia, depression-dejection, vigor-activity, confusion-bewilderment. Responses to questions are scored with the following numerical values: Not at all = 1, A little = 2, Moderate = 3, Quite a bit = 4, Extremely = 5. A total score for a domain was obtained by summing the responses of individual items in the domain. The total POMS score can range from \"65\" to \"325.\" Each subject's total POMS score at baseline and at Week 4 and Week 12 were used to calculate the percent of participants with less disturbance in mood at Week 4 and Week 12 compared to baseline. The percent of participants with less disturbance in mood is reported below.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.29","spread":null},{"groupId":"OG001","value":"35.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.90","spread":null},{"groupId":"OG001","value":"34.25","spread":null}]}]}]},{"type":"SECONDARY","title":"BMI Change From Baseline (kg/m2), Median","description":"Subjects were weighed at each clinic visit and reported the number of hot flashes using an electronic diary.\n\nAssessment of the effect of Brisdelle compared with placebo on body mass index.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.17","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in Hot Flash Severity at Week 4 and Week 12","description":"Subjects recorded the number of hot flashes per week using an electronic diary. Severity score for hot flashes for each subject was calculated as the sum of 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of moderate and severe hot flashes.\n\nWeekly Severity Score = (2•Fm +3•FS)/(Fm + FS) Daily Severity Score = {(2•F) m +3•FS)/(Fm + FS)}/7 Where, Fm= Frequency of Moderate Hot Flashes Fs = Frequency of Severe Hot Flashes The calculated severity score is reported below.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.528","spread":"0.30"},{"groupId":"OG001","value":"2.526","spread":"0.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.091","spread":"0.25"},{"groupId":"OG001","value":"-0.046","spread":"0.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.104","spread":"0.29"},{"groupId":"OG001","value":"-0.084","spread":"0.29"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":301},"commonTop":["Headache","Nasopharyngitis","Diarrhoea","Sinusitis","Nausea"]}}}